To request a FREE 2-week trial subscription, please signup. NOTE - this can take up to 48hrs to be approved.

J.P. Morgan analyst Chris Schott maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,150.00.

This webinar explores how immersing yourself in the patient experience can add measurable, actionable value to your approach ...

Amgen's move follows the lifting of a temporary injunction on the launch of its Pavblu-branded biosimilar by the US Court of ...

Check out the latest brokerage calls and analyst comments on the stocks in action today. Our coverage includes HUL, Coforge, Bajaj Finance and more.

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on Regeneron (REGN – Research Report). The associated price ...

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as ...

Me CEO Anne Wojcicki continues to maintain a strong outlook despite recent high-profile stumbles. “We are a long-term company ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based ...

Recent health news includes a court ruling allowing Amgen's Eylea biosimilar launch, Starboard criticizing Kenvue's skin ...

Recent health news includes Amgen's launch of an Eylea biosimilar in the U.S., Slovakia's bird flu outbreak, and China's ...